Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Avicanna ( (TSE:AVCN) ) has shared an update.
Avicanna Inc., a Toronto-listed biopharmaceutical company focused on plant-derived cannabinoid-based products, has built a diversified commercial platform spanning branded medical cannabis formulations, a patient-centric care and distribution platform, indication-specific pharmaceutical candidates, and an active pharmaceutical ingredient business that supports its own brands and international partners. The company announced the resignation of board member John McVicar and the appointment of seasoned pharma executive Ozgur Kilic to its board, a move expected to bolster Avicanna’s strategic and financial leadership as it targets expanded U.S. presence and a stronger international footprint for its differentiated product portfolio and developing drug pipeline.
Kilic brings more than two decades of global experience as a CEO, CFO, and COO across public and private equity-backed pharmaceutical companies in the U.S., U.K., Italy, and Switzerland, complementing Avicanna’s ambitions in dermatology, chronic pain, and neurological indications. His appointment underscores the company’s push to capitalize on what it describes as a value inflection point, with more than 50 commercialized products, growing medical education initiatives, and an integrated supply chain positioning it to compete more aggressively in regulated cannabinoid therapeutics markets.
The most recent analyst rating on (TSE:AVCN) stock is a Hold with a C$0.19 price target. To see the full list of analyst forecasts on Avicanna stock, see the TSE:AVCN Stock Forecast page.
Spark’s Take on AVCN Stock
According to Spark, TipRanks’ AI Analyst, AVCN is a Neutral.
The score is held back primarily by continued losses and negative cash flow despite strong revenue growth and improving gross margins, plus a weak technical trend (price below major moving averages and negative MACD). Valuation also screens poorly due to the negative P/E, consistent with the lack of current profitability.
To see Spark’s full report on AVCN stock, click here.
More about Avicanna
Avicanna Inc. is an international biopharmaceutical company specializing in the commercialization of proprietary, evidence-based cannabinoid products for global medical and pharmaceutical markets. The Toronto-based firm operates across four pillars, including its RHO Phyto medical cannabis formulary, the MyMedi.ca medical cannabis care platform, a clinical-stage pharmaceutical pipeline, and Aureus Santa Marta active pharmaceutical ingredients supplying CBD, THC, and CBG worldwide.
YTD Price Performance: -33.33%
Average Trading Volume: 55,890
Technical Sentiment Signal: Sell
Current Market Cap: C$18.85M
Find detailed analytics on AVCN stock on TipRanks’ Stock Analysis page.